Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the company withdrew its 2025 guidance [3][4]. Summary by Relevant Sections Allegations - The complaint alleges that Centene's management made overwhelmingly positive statements to investors while concealing material adverse facts about the company's true enrollment and morbidity rates [3]. - On July 1, 2025, Centene issued a press release withdrawing its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3]. Stock Performance - Following the announcement on July 1, 2025, Centene's stock price plummeted from $56.65 per share to $33.78 per share on July 2, 2025, marking a decline of 40.4% [3]. Class Action Details - The class period for the lawsuit is defined as December 12, 2024, to June 30, 2025, and shareholders are encouraged to register for participation in the class action [3][4]. - The deadline for shareholders to seek lead plaintiff status is September 8, 2025, and there is no cost or obligation to participate in the case [4]. Law Firm Information - The Gross Law Firm is representing the shareholders and is recognized for its commitment to protecting investors' rights against deceit and fraud [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Centene Corporation securities between December 12, 2024, and June 30, 2025, about the September 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Centene common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The lead plaintiff must file a motion with the Court by September 8, 2025, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Background - The lawsuit alleges that Centene's defendants provided misleading information regarding the company's expected revenue guidance and adjusted diluted earnings per share (EPS) for the 2025 fiscal year [4] - Positive statements about Centene's enrollment and morbidity rates were made while concealing material adverse facts about the true state of these metrics [4]

Core Viewpoint - Molina (MOH) is expected to report quarterly earnings of $5.50 per share, a decline of 6.1% year-over-year, with revenues projected at $10.84 billion, reflecting a 9.7% increase compared to the previous year [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been revised downward by 3.8%, indicating a reassessment by analysts [2]. - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Revenue- Premium tax revenue' at $377.16 million, a year-over-year increase of 26.6% [5]. - The consensus for 'Revenue- Premium revenue' is $10.44 billion, indicating a 10.5% increase from the prior year [5]. - 'Revenue- Premium revenue- Medicare' is projected to reach $1.47 billion, reflecting a 1.9% increase year-over-year [5]. - 'Revenue- Other revenue' is expected to be $22.84 million, an 8.8% increase from the previous year [6]. Membership and MCR Metrics - 'MCR - Total' is projected at 88.9%, up from 88.6% in the same quarter last year [6]. - 'MCR - Medicare' is expected to reach 85.4%, compared to 84.9% a year ago [6]. - 'MCR - Marketplace' is forecasted at 77.5%, an increase from 71.6% year-over-year [7]. - 'Ending Membership by Program - Total' is estimated at 5.79 million, up from 5.58 million in the same quarter last year [7]. - 'Ending Membership by Program - Medicaid' is projected at 4.88 million, slightly down from 4.94 million a year ago [7]. - 'Ending Membership by Program - Medicare' is expected to be 261.48 thousand, up from 251.00 thousand last year [8]. - 'Ending Membership by Program - Marketplaces' is projected at 629.31 thousand, significantly up from 386.00 thousand in the previous year [8]. - 'MCR - Medicaid' is expected to reach 91.2%, compared to 90.8% a year ago [9]. Stock Performance - Molina shares have decreased by 37.8% over the past month, contrasting with a 5.4% increase in the Zacks S&P 500 composite [9].

CONTACT US HERE: https://securitiesclasslaw.com/securities/centene-corporation-loss-submission-form/?id=157185&from=4 CLASS PERIOD: December 12, 2024 to June 30, 2025 NEW YORK, July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Centene Corporation (NYSE: CNC). ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or conceali ...

Well, many Americans have felt the frustration of getting a healthc care insurance denial leading to hours and hours on the phone, trading emails with the carrier, and oftentimes never getting a solution. But there's a new company that's looking to change all of that. Our next guest runs a platform that uses AI to appeal denials for care to treat 70 autoimmune conditions like Crohn's disease and others.Patients fill out a form and AI handles the leg work scanning health care plans and relevant state and fed ...

Core Insights - Renalytix Plc and MVP Health Care have formed a partnership to enhance access to kidney care for individuals with type 2 diabetes and chronic kidney disease, aiming to improve health outcomes and reduce health disparities [1][2] - The collaboration will implement the kidneyintelX.dkd™ FDA-approved test across MVP's network, facilitating earlier interventions and personalized care plans for patients [2][3] - The kidneyintelX.dkd™ test will be available to all MVP customers in New York, including those with Medicare or Medicaid, and is endorsed by KDIGO, the international clinical guideline organization for kidney disease [3] Company Overview - Renalytix is an AI-enabled in vitro diagnostics company focused on improving clinical management of kidney disease, with FDA approval and Medicare reimbursement for the kidneyintelX.dkd test [5] - MVP Health Care is a not-for-profit health insurer serving New York and Vermont, dedicated to enhancing the well-being of its members and communities [6] Impact on Patient Care - The partnership aims to identify patients at higher risk for kidney function decline earlier, allowing for targeted resources and therapeutic options, which can lead to better management of cardiovascular and metabolic conditions [1][4] - The use of kidneyintelX.dkd has shown measurable improvements in patient outcomes and quality metrics, particularly in managing blood pressure and HbA1c levels in high-risk populations [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Centene Corporation due to misleading statements regarding the company's enrollment and morbidity rates, which led to significant stock price declines [3][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Centene to contact them for legal options, particularly those who purchased securities between December 12, 2024, and June 30, 2025 [1][3]. - A federal securities class action has been filed against Centene, with a deadline of September 8, 2025, for investors to seek the role of lead plaintiff [3][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Company Performance and Stock Impact - Centene provided positive statements to investors while concealing adverse facts about its enrollment and morbidity rates, leading to a significant loss of investor trust [5]. - On July 1, 2025, Centene withdrew its 2025 guidance, stating that its market growth across 22 states was lower than expected, resulting in a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [5]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $33.78 per share, marking a decline of 40.4% in just one day [6].

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, following significant discrepancies between the company's financial guidance and actual market conditions [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities [2]. - Investors have until September 8, 2025, to request to lead the case [2]. Group 2: Company Background - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 3: Financial Guidance and Market Conditions - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions revealed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Group 4: Stock Performance - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report indicated lower than expected market growth and higher morbidity rates, leading to a stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - A securities class action lawsuit has been filed against Centene Corporation for allegedly making materially false and misleading statements regarding its business operations and market performance during the specified Class Period from December 12, 2024, to June 30, 2025 [1][2]. Group 1: Allegations Against Centene - The lawsuit claims that Centene's management misrepresented the company's marketplace share, indicating lower-than-expected enrollment and increased market morbidity [2]. - It is alleged that the statements made by Centene's management about the company's business and prospects were materially false and lacked a reasonable basis throughout the Class Period [2]. Group 2: Lead Plaintiff Process - Investors in Centene have until September 8, 2025, to seek appointment as a lead plaintiff representative in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is a law firm that specializes in prosecuting class actions and has a reputation for recovering significant amounts for victims of corporate misconduct [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Centene Corporation securities during the specified Class Period, indicating potential legal issues for the company related to misleading statements about its financial performance [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for investors who purchased Centene common stock between December 12, 2024, and June 30, 2025, and aims to provide compensation without out-of-pocket fees through a contingency fee arrangement [2][5]. - The lawsuit alleges that Centene's management provided materially false and misleading information regarding the company's expected revenue guidance and adjusted diluted earnings per share (EPS) for the 2025 fiscal year, while concealing adverse facts about enrollment and morbidity rates [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions, highlighting the Rosen Law Firm's achievements in this area, including significant settlements and recognition in the legal community [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone, showcasing its capability in handling such cases [4]. Group 3: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly for more information [3][6]. - It is noted that no class has been certified yet, meaning investors are not represented unless they retain counsel, and participation as a lead plaintiff is not necessary for potential recovery [7].